Rimonabant (Acomplia) Powder (168273-06-1)

Rimonabant (Acomplia) Powder (168273-06-1)

Product Name: Rimonabant
Synonyms: ACOMPLIA;RIMONABANT;RIMONABANT(ACOMPLIA,SR141716);5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide;1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-;5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide;A 281;Sr 141716
CAS: 168273-06-1
MF: C22H21Cl3N4O
MW: 463.79
Assay 99%
Appearance: White Powder
Usage Weight loss powders/ Rimonabant is a selective antagonist
Product Categories: Weight Loss;SR141716

Rimonabant (Acomplia) Description:

Rimonabant (Acomplia) is an efficient cannabinoid receptor antagonist that lowers your food yearnings and therefore helps you to burn fat without excessive emotional stress. It does not work on its own, in lieu of in combination with diet programs and regular exercising.
If you have an impaired liver function, kidney function, if you are more youthful compared to 18 or are getting treatment for epilepsy, you are not expected to begin taking this medicine without chatting to your physician.
There are insufficient information on Rimonabant being used in people younger compared to 18 so also if you make such a choice you are not expected to begin taking this drug without speaking with your doctor first. Your health treatment supplier could begin you on a lower amount and after that raise it to make certain you are profiting from the procedure, the normal recommended dose is 20 mg. that you are expected to take at morning meal time.

Rimonabant (Acomplia) Application:

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.

Rimonabant works by blocking endogenous cannabinoid from binding to neuronal CB1 receptors. The activation of these receptors by endogenous cannabinoids, such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.

Rimonabant (Acomplia) Use:

Rimonabant is a weight loss drug, can significantly reduce weight, reduce waist circumference and reduce risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the presence of clinical obesity or heart disease people at risk.

Rimonabant as a new weight loss drug, can also be used to quit smoking. Not only lose weight, but also lower blood pressure, cholesterol and blood sugar, clinical study found that subjects taking one to two months later, the weight can be reduced on average six to eight kilograms.

Rimonabant (Acomplia) COA: